TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell

See also
Status	Clinical Trial	Phase
Enrolling by invitation	`NCT01804686` - A Long-term Extension Study of PCI-32765 (Ibrutinib)	Phase 3
Recruiting	`NCT05976763` - Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma	Phase 3
Recruiting	`NCT03676504` - Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR	Phase 1/Phase 2
Recruiting	`NCT05365659` - IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas	Phase 1
Recruiting	`NCT05471843` - Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma	Phase 1/Phase 2
Recruiting	`NCT05076097` - A Study of OLR in First-line Treatment of Mantle Cell Lymphoma	Phase 2
Active, not recruiting	`NCT04082936` - A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma	Phase 1/Phase 2
Active, not recruiting	`NCT03891355` - Carfilzomib + Lenalidomide and Dexamethasone for BTK Inhibitors Relapsed-refractory or Intolerant MCL	Phase 2
Recruiting	`NCT04883437` - Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas	Phase 2
Terminated	`NCT03585725` - A Pilot Investigator-Initiated Study of Ribavirin in Indolent Follicular Lymphoma and Mantle Cell Lymphoma	Early Phase 1
Recruiting	`NCT02892695` - PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma	Phase 1/Phase 2
Terminated	`NCT02877082` - Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients	Phase 2
Completed	`NCT01665768` - Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma	Phase 2
Completed	`NCT01437709` - Ofatumumab With or Without Bendamustine for Patients With Mantle Cell Lymphoma Ineligible for Autologous Stem Cell Transplant	Phase 2
Completed	`NCT00963534` - Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma.	Phase 1/Phase 2
Completed	`NCT00921414` - Mantel Cell Lymphoma Efficacy of Rituximab Maintenance	Phase 3
Withdrawn	`NCT00541424` - Combined CT Colonography and PET Imaging in Mantle Cell Lymphoma	N/A
Completed	`NCT01456351` - Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab	Phase 3
Completed	`NCT01851551` - Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL	Phase 1/Phase 2
Completed	`NCT03295240` - The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma	Early Phase 1

NCT number	NCT06106841
Study type	Interventional
Source	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Contact	Lugui Qiu, Doctor
Phone	13821266636
Email	Qiulg@ihcams.ac.cn
Status	Recruiting
Phase	Phase 1/Phase 2
Start date	October 5, 2023
Completion date	December 2024

TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms